How did Tenet's financial position change in fiscal 1996?

Total assets were $8.332 billion at May 31, 1996, compared with $7.918 billion a year earlier. Shareholders' equity increased to $2.636 billion from $1.986 billion, and long-term debt excluding the current portion declined to $3.191 billion from $3.273 billion. The company attributed the improvement largely to asset sales and the elimination of required quarterly term loan repayments under the March 1996 credit agreement.

What drove the large increase in revenue and interest expense?

The filing attributes the increase in net operating revenues to the American Medical Holdings merger, which was included for a full year in fiscal 1996 but only for the fourth quarter in fiscal 1995. Interest expense, net of capitalized portion, rose to $312 million from $138 million, which the company primarily attributes to the AMH acquisition and the notes and bank loans used to finance it.

What are the main risks identified in the filing?

The filing highlights psychiatric malpractice and fraud litigation, a shareholder class action relating to 1993 statements, and the AMH merger class actions, which have been settled. It also notes ongoing pressure from managed care pricing and expected Medicare and Medicaid reimbursement reductions. A November 5, 1996 California ballot measure on nurse-to-patient ratios could materially increase costs if passed and not passed through to payors. The IRS is also examining federal returns for fiscal years 1986 through 1994.

What is Tenet's current exposure to the Vencor and Total Renal Care investments?

At May 31, 1996, Tenet held an approximately 11.5% interest in Vencor, with 8,301,067 shares of Vencor common stock whose market value was approximately $263 million. The $320 million 6% Exchangeable Subordinated Notes are exchangeable into these Vencor shares after November 6, 1997. The company held an approximately 11.6% interest in Total Renal Care with a carrying value of $49 million and a market value of approximately $124 million.

How much capacity did Tenet have to fund growth?

Tenet had approximately $575 million of unused borrowing capacity under its new $1.55 billion revolving credit agreement at May 31, 1996, which matures March 1, 2001. The company stated that its liquidity, along with this credit availability, should be adequate for debt service and planned capital expenditures over the short term (up to 18 months) and long term (18 months to three years). Capital expenditures are expected to be approximately $300 million to $400 million annually before significant acquisitions.

THC 10-K FY1996 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed August 26, 1996. Cited figures are marked; the original filing is the authoritative source.

Tenet Healthcare Corporation (filed as Tenet Healthcare Corporation, Santa Barbara, California; NYSE and Pacific: THC) filed this Form 10-K for the fiscal year ended May 31, 1996.

The company describes itself as the second-largest investor-owned healthcare services company in the United States, operating 74 domestic general hospitals with 16,666 licensed beds in 13 states, and identifies healthcare as its only material business segment. Fiscal 1996 was defined by the completion of its asset monetization program: substantially all international operations were sold, the Westminster stake was sold for approximately $120 million^a, and the Hillhaven preferred stock was redeemed for about $92 million. Net operating revenues were $5.559 billion, compared with $3.318 billion in fiscal 1995, and income from continuing operations was $398 million ($1.90 primary EPS).

Fiscal 1996 results include net gains on disposals and asset sales of $346 million^b, and $86 million of impairment losses. The balance sheet improved meaningfully. Total assets were $8.332 billion, shareholders' equity was $2.636 billion, and long-term debt excluding the current portion was $3.191 billion, down from $3.273 billion.

The company's long-term debt-to-equity ratio was approximately 1.21-to-1 at May 31, 1996, down from 1.85-to-1 at March 1, 1995. In March 1996 Tenet entered a five-year, $1.55 billion^c unsecured revolving credit agreement, of which $575 million was unused at May 31, 1996. Senior debt ratings were BB by Standard & Poor's and Ba1 by Moody's.

Interest expense rose to $312 million^d from $138 million, reflecting the March 1995 acquisition of American Medical Holdings, Inc. Investors should weigh several risks described in the filing. Psychiatric malpractice and fraud litigation remains a significant exposure, though the company says it does not expect material adverse effects beyond its reserves.

Medicare and Medicaid reimbursement pressure continues, with the company stating that payments to hospitals are expected to be reduced by future legislation. A California ballot initiative on nurse-to-patient ratios, scheduled for November 5, 1996, could materially affect costs if passed and not passed through to payors.

02—Key points

Key Highlights

Net operating revenues of $5.559 billion in fiscal 1996, up from $3.318 billion in fiscal 1995, reflecting the full-year inclusion of the AMH acquisition.
Income from continuing operations of $398 million ($1.90 primary EPS), including $346 million of net gains on disposals and asset sales and $86 million of impairment losses.
Completed sale of substantially all international operations and most non-core assets, including Singapore hospitals, AME, Westminster (about $120 million), and Hillhaven preferred stock (about $92 million).
Long-term debt-to-equity ratio improved to approximately 1.21-to-1 at May 31, 1996, from 1.85-to-1 at March 1, 1995; shareholders' equity rose to $2.636 billion.
New $1.55 billion unsecured revolving credit agreement (March 1996) with $575 million available at May 31, 1996; senior debt upgraded to Ba1 by Moody's and BB by Standard & Poor's.
Medicare represented approximately 40% of net patient revenues of domestic general hospitals in 1996; the filing notes that future legislation is expected to reduce hospital payments.
Continued exposure to psychiatric malpractice and fraud litigation, including Texas state court suits with approximately 740 plaintiffs and a purported class action in Texas.

03—Questions

Frequently Asked Questions

How did Tenet's financial position change in fiscal 1996?
Total assets were $8.332 billion at May 31, 1996, compared with $7.918 billion a year earlier. Shareholders' equity increased to $2.636 billion from $1.986 billion, and long-term debt excluding the current portion declined to $3.191 billion from $3.273 billion. The company attributed the improvement largely to asset sales and the elimination of required quarterly term loan repayments under the March 1996 credit agreement.
What drove the large increase in revenue and interest expense?
The filing attributes the increase in net operating revenues to the American Medical Holdings merger, which was included for a full year in fiscal 1996 but only for the fourth quarter in fiscal 1995. Interest expense, net of capitalized portion, rose to $312 million from $138 million, which the company primarily attributes to the AMH acquisition and the notes and bank loans used to finance it.
What are the main risks identified in the filing?
The filing highlights psychiatric malpractice and fraud litigation, a shareholder class action relating to 1993 statements, and the AMH merger class actions, which have been settled. It also notes ongoing pressure from managed care pricing and expected Medicare and Medicaid reimbursement reductions. A November 5, 1996 California ballot measure on nurse-to-patient ratios could materially increase costs if passed and not passed through to payors. The IRS is also examining federal returns for fiscal years 1986 through 1994.
What is Tenet's current exposure to the Vencor and Total Renal Care investments?
At May 31, 1996, Tenet held an approximately 11.5% interest in Vencor, with 8,301,067 shares of Vencor common stock whose market value was approximately $263 million. The $320 million 6% Exchangeable Subordinated Notes are exchangeable into these Vencor shares after November 6, 1997. The company held an approximately 11.6% interest in Total Renal Care with a carrying value of $49 million and a market value of approximately $124 million.
How much capacity did Tenet have to fund growth?
Tenet had approximately $575 million of unused borrowing capacity under its new $1.55 billion revolving credit agreement at May 31, 1996, which matures March 1, 2001. The company stated that its liquidity, along with this credit availability, should be adequate for debt service and planned capital expenditures over the short term (up to 18 months) and long term (18 months to three years). Capital expenditures are expected to be approximately $300 million to $400 million annually before significant acquisitions.

04—Continue

← View all 10-K filings